We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Show more
TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.38 | 16.814159292 | 2.26 | 2.6891 | 2.155 | 999821 | 2.32516129 | CS |
4 | -0.41 | -13.4426229508 | 3.05 | 3.1 | 2.15 | 640926 | 2.48333832 | CS |
12 | -1.34 | -33.6683417085 | 3.98 | 5.07 | 2.15 | 428992 | 3.35137316 | CS |
26 | -0.74 | -21.8934911243 | 3.38 | 5.07 | 2.15 | 443951 | 3.64949142 | CS |
52 | -2.62 | -49.8098859316 | 5.26 | 6.35 | 2 | 343672 | 3.60976681 | CS |
156 | -5.36 | -67 | 8 | 37.55 | 2 | 354774 | 6.19893107 | CS |
260 | -5.36 | -67 | 8 | 37.55 | 2 | 354774 | 6.19893107 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions